12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression

NCT02363738 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Bipolar Depression

Interventions

DRUG: Infliximab
OTHER: Saline

Sponsor

University Health Network, Toronto

Collaborators

[object Object]
[object Object]